Eqis Capital Management Inc. Decreases Stake in GALAPAGOS NV/S (NASDAQ:GLPG)

Eqis Capital Management Inc. lowered its position in GALAPAGOS NV/S (NASDAQ:GLPG) by 1.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 24,159 shares of the biotechnology company’s stock after selling 412 shares during the period. Eqis Capital Management Inc.’s holdings in GALAPAGOS NV/S were worth $3,688,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Bessemer Group Inc. purchased a new stake in shares of GALAPAGOS NV/S during the 2nd quarter valued at approximately $48,447,000. Morgan Stanley lifted its stake in GALAPAGOS NV/S by 1.7% during the second quarter. Morgan Stanley now owns 65,837 shares of the biotechnology company’s stock worth $8,488,000 after purchasing an additional 1,111 shares during the last quarter. Victory Capital Management Inc. lifted its stake in GALAPAGOS NV/S by 35.0% during the second quarter. Victory Capital Management Inc. now owns 32,826 shares of the biotechnology company’s stock worth $4,232,000 after purchasing an additional 8,510 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its stake in GALAPAGOS NV/S by 134.4% during the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 29,300 shares of the biotechnology company’s stock worth $3,778,000 after purchasing an additional 16,800 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in GALAPAGOS NV/S by 220.6% during the second quarter. Bank of America Corp DE now owns 25,511 shares of the biotechnology company’s stock worth $3,290,000 after purchasing an additional 17,554 shares during the last quarter. Institutional investors own 15.57% of the company’s stock.

GLPG stock traded up $2.09 on Tuesday, reaching $191.72. 669 shares of the company’s stock were exchanged, compared to its average volume of 154,015. The stock has a fifty day moving average of $164.21 and a 200-day moving average of $148.86. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $191.63. The firm has a market cap of $10.35 billion, a PE ratio of -290.48 and a beta of 1.58. The company has a quick ratio of 8.95, a current ratio of 8.95 and a debt-to-equity ratio of 0.01.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its quarterly earnings data on Thursday, October 24th. The biotechnology company reported $8.72 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $10.13. The firm had revenue of $715.97 million for the quarter, compared to analyst estimates of $52.26 million. GALAPAGOS NV/S had a return on equity of 25.34% and a net margin of 32.09%. On average, equities research analysts predict that GALAPAGOS NV/S will post 8 EPS for the current fiscal year.

Several equities research analysts recently weighed in on the company. Jefferies Financial Group cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Monday, July 29th. ValuEngine cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Stifel Nicolaus boosted their target price on GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Raymond James cut GALAPAGOS NV/S from a “strong-buy” rating to a “market perform” rating in a research note on Monday, July 15th. Finally, Royal Bank of Canada boosted their target price on GALAPAGOS NV/S to $171.00 in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $175.22.

GALAPAGOS NV/S Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: Stop Order

Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GALAPAGOS NV/S (NASDAQ:GLPG).

Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.